Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action

Table 3 Clinical Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) used in the calibration.

Drug	Dose	Time (weeks)	ADAS-Cog Effect	Drug	Dose	Time (weeks)	ADAS-Cog Effect
Placebo	0	12	0.27	Galantamine	16	26	-1.10
Placebo	0	26	1.87	Galantamine	16	52	1.49
Placebo	0	52	5.07	Galantamine	24	12	-1.96
Placebo	0	78	7.10	Galantamine	24	26	-1.10
Donepezil	5	12	-1.77	Galantamine	24	52	1.49
Donepezil	5	26	-0.27	Rivastigmine	6	12	-0.66
Donepezil	5	52	2.87	Rivastigmine	6	26	0.70
Donepezil	10	12	-2.12	Rivastigmine	6	52	3.71
Donepezil	10	26	-0.64	Rivastigmine	12	12	-1.82
Donepezil	10	52	2.48	Rivastigmine	12	26	-0.77
Galantamine	8	12	-1.77	Rivastigmine	12	52	2.01
Galantamine	8	26	-0.95	SB-742457	5	26	-0.22
Galantamine	8	52	1.29	SB-742457	15	26	-0.66
Galantamine	16	12	-1.96	SB-742457	35	26	-1.12

Clinical ADAS-Cog changes for different drugs, doses and time points, used in the calibration of the AD network model. The values are derived from the population kinetic model based upon a meta-analysis and other reports on placebo and 5-HT₆ antagonists.

ISSN: 1758-9193